Abstracts tagged "myopathy and myositis"

Abstract Number: 319 • 2018 ACR/ARHP Annual Meeting
Patterns of Muscle Oedema, Atrophy and Fatty Replacement in the Idiopathic Inflammatory Myopathies: A Single-Centre Retrospective Review of Magnetic Resonance Imaging Data
Jessica Day^1,2, Nicholas Bajic³, Sheridan Gentili⁴, Sandy Patel⁵ and Vidya Limaye⁶, ¹Rheumatology, Royal Adelaide Hospital, Adelaide, Australia, ²Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ³Dr Jones and Partners St Andrew's and Calvary Wakefield Hospitals, Adeliad, Australia, ⁴University of South Australia, Adelaide, Australia, ⁵Radiology, Royal Adelaide Hospital, Adelaide, Australia, ⁶Rheumatology, The Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: Magnetic resonance imaging (MRI) has been used as a non-invasive tool to aid diagnosis and monitor disease activity in the idiopathic inflammatory myopathies (IIMs).…
Abstract Number: 380 • 2018 ACR/ARHP Annual Meeting
A New Tool to Assess Muscle Strength in Polymyositis and Dermatomyositis: Hand-Held Dynamometry
Didem Saygin¹, Chester V. Oddis², Siamak Moghadam-Kia³, Diane Koontz⁴, Nicole Marie Neiman³ and Rohit Aggarwal⁵, ¹Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Division of Rheumatology and Clinical Immunology, Department of Medicine, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, ³Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Internal Medicine Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine / Rheumatology, University of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) is a group of systemic autoimmune diseases characterized by proximal muscle weakness, which is often assessed clinically using manual muscle…
Abstract Number: 390 • 2018 ACR/ARHP Annual Meeting
Severe Axial and Pelvifemoral Muscle Damage in Immune-Mediated Necrotizing Myopathy Evaluated By Whole-Body MRI
Océane Landon-Cardinal¹, Cedi Koumako², Giulia Hardouin³, Benjamin Granger³, Harmen Reyngoudt², Jean-Marc Boisserie², Aude Rigolet¹, Baptiste Hervier¹, Nicolas Champtiaux¹, Perrine Guillaume¹, Mathieu Vautier¹, Pierre Carlier², Olivier Benveniste¹ and Yves Allenbach¹, ¹Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ²Laboratoire de RMN AIM & CEA, Centre d'Explorations Fonctionnelles, Institut de Myologie, Paris, France, ³Département de Biostatistiques, Santé Publique et Information Médicale, Groupe hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: Immune-mediated necrotizing myopathies (IMNM) are a severe condition with early muscle damage attested by MRI of thigh muscles. Presence of damage in the other…
Abstract Number: 1331 • 2018 ACR/ARHP Annual Meeting
Moving from Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody to Anti-Melanoma Differentiation-Associated Gene 5 Syndrome
Yves Allenbach¹, Yurdagul Uzunhan², Ségolène Toquet³, Gaëlle Leroux⁴, Laure Gallay⁵, Aude Rigolet⁶, Baptiste Hervier⁶, Nicolas Champtiaux⁶, Mathieu Vautier⁶, Perrine Guillaume⁶, Nicolas Limal⁷, Alain Meyer⁸, Christophe Deligny⁹, Bernard Bonnotte¹⁰, Hervé Devilliers¹¹, Sylvain Audia¹², Maxime Samson¹³, Amélie Servettaz¹⁴, Nathalie Costedoat¹⁵, David Saadoun¹⁶, elisabeth diot¹⁷, Alice Berezne¹⁸, Arsène Mékinian¹⁹, Kuberaka Mariampillai²⁰, Hilario Nunes² and Olivier Benveniste⁶, ¹Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ²Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ³Sorbonne Universités, UPMC Univ Paris 06, INSERM UMRS_974, CNRS FRE 3617, Center of Research in Myology., Paris, France, ⁴Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁵Internal Medicine, Université de Lyon - CHU Lyon, Lyon, France, ⁶Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ⁷Internal Medicine, APHP - Henri Mondor Hospital, Paris, France, ⁸15Département de Rhumatologie, Centre de Référence des Maladies Auto-immunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁹Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique, ¹⁰Dijon, Dijon, France, ¹¹Service de Médecine Interne et Maladies Systémiques, CHU de Dijon, Dijon, France, ¹²Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France, ¹³Dijon University Hospital, Dijon, France, ¹⁴Internal Medicine, CHU - Reims University, Reims, France, ¹⁵Internal Medicine, Paris Descartes Université - APHP, paris, France, ¹⁶Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, ¹⁷Internal Medicine, Université Tours - CHU, Tours, France, ¹⁸Internal Medicine, CH Annecy, Annecy, France, ¹⁹Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ²⁰Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Neuro-Musculaires Paris Est, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié-Salpêtrière, Paris, France
Background/Purpose: Dermatomyositis (DM) is a heterogenous group of diseases ranging from skin limited disorders to non-specific auto-immune diseases with patients suffering from additional extra-cutaneous manifestations.…
Abstract Number: 1343 • 2018 ACR/ARHP Annual Meeting
A Novel Autoantibody Against DNA Damage Binding Protein-1 in Idiopathic Inflammatory Myopathy
Yuji Hosono^1,2, Ran Nakashima¹, Koji Kitagori¹, Kosaku Murakami¹, Hajime Yoshifuji¹, Koichiro Ohmura³ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Many kinds of autoantibodies are detected in idiopathic inflammatory myopathy (IIM) patients. Some of them are useful to diagnose, predict the clinical course, and…
Abstract Number: 2173 • 2017 ACR/ARHP Annual Meeting
Characteristics Unique to MDA5 and Anti-Ro/SSA-52 Kda Dual Antibody Positive Patients with Inflammatory Myopathies
Juan J Maya, Olga Pinkston, Florentina Berianu, Benjamin Wang and Andy Abril, Rheumatology, Mayo Clinic Florida, Jacksonville, FL
Background/Purpose: The anti-melanoma differentiation-associated gene 5 antibody (MDA5) was recently classified as a myositis-specific antibody (MSA), and has been associated with rapidly progressive interstitial lung…
Abstract Number: 2323 • 2016 ACR/ARHP Annual Meeting
Evaluation of Case-Finding Algorithms for Identification of Patients with Dermatomyositis
Kevin Byram¹ and Narender Annapureddy², ¹Internal Medicine, Vanderbilt University, Nashville, TN, ²Rheumatology and Immunology, Vanderbilt University, Nashville, TN
Background/Purpose: In order to enable meaningful clinical care and research, accurate algorithms are needed to identify patients with dermatomyositis (DM). In this study, we aimed…
Abstract Number: 2327 • 2016 ACR/ARHP Annual Meeting
Cardiac Involvement in Inflammatory Myopathies: A Report from the Remicam Registry
rina molina¹, Beatriz E. Joven², Laura Nuño³, Francisco Javier López Longo⁴, MARIA JESUS GARCIA DE YEBENES Y PROUS⁵, VAlentina Maldonado⁶, Carmen Larena⁷, Irene Llorente⁸, Eva Tomero⁹, Carmen Barbadillo¹⁰, Paloma Garcia De La Peña¹¹, Lucía Ruiz Gutiérrez¹², Juan Carlos Lopez-Robledillo¹³, Henry Moruno Cruz¹², Ana Pérez Gómez¹², Tatiana Cobo-Ibáñez¹⁴, Raquel Almodóvar González¹⁵, Leticia Lojo¹⁶ and Patricia Carreira¹⁷, ¹MADRID, Hospital 12 de Octubre, MADRID, Spain, ²Rheumatology, Hospital 12 de Octubre, Madrid, Spain, ³Servicio de Reumatologia, Hospital Universitario La Paz, Madrid, Spain, ⁴Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, ⁵INSTITUTO DE SALUD MUSCULOESQUELÉTICA, MADRID, Spain, ⁶Hospital Ramón y Cajal, Madrid, Spain, ⁷Hospital Gregorio Marañón, Madrid, Spain, ⁸Rheumatology, H.U. La Princesa, Madrid, Spain, ⁹Hospital La Princesa. Madrid., Madrid, Spain, ¹⁰Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹¹Rheumatology, Hospital Madrid Norte Sanchinarro, Madrid, Spain, ¹²University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ¹³Hospital Niño Jesus, Madrid, Spain, ¹⁴Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹⁵Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ¹⁶Rheumatology, Hospital Universitario La Paz, Spain, Spain, ¹⁷Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain
Background/Purpose: A multicenter retrospective study from the REMICAM registry was performed. All patients were diagnosed with IM according to Bohan and Peter criteria, followed…
Abstract Number: 1255 • 2014 ACR/ARHP Annual Meeting
Pathogenic Role of Tyrosyl–Transfer RNA Synthetase in Anti-Synthetase Syndrome
Yuko Okamoto¹, Yasuhiro Katsumata¹, Yasushi Kawaguchi¹, Manabu Kawamoto¹, Ken Iwaki², Miki Miyanokoshi², Keisuke Wakasugi², Koji Tahara³, Kaori Ito³, Hiroaki Hattori³, Takahisa Gono¹, Masanori Hanaoka¹, Tomoaki Higuchi¹, Hidenaga Kawasumi¹ and Hisashi Yamanaka⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan, ³Advanced Medical Technology and Development, BML, Saitama, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose : Autoantibodies directed against the aminoacyl transfer RNA (tRNA) synthetases are associated with myositis, arthritis, Raynaud’s phenomenon, mechanic’s hands, fever, and interstitial lung disease,…
Abstract Number: 913 • 2014 ACR/ARHP Annual Meeting
Long Term Outcomes of Patients with Moderate Creatine Kinase (CK) Elevation Seen in a Rheumatology Clinic
Lyudmila Kirillova¹, Abraham Tacang², Andrea Berger³, Thomas M. Harrington⁴ and Androniki Bili¹, ¹Rheumatology, Geisinger Health System, Danville, PA, ²Internal medicine - Pediatric, Geisinger Health System, Danville, PA, ³Center for Health Research, Geisinger Health System, Danville, PA, ⁴Dept of Rheumatology, Geisinger Health System, Danville, PA
Background/Purpose: Asymptomatic or mildly symptomatic patients with moderate creatine kinase (CK) elevation are commonly referred to rheumatologists. In patients without a clearly established diagnosis, the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].